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abstract
Introduction: High level of vitamin D is associated with a better health status. The role of 
vitamin D deficiency in the incidence of cardiovascular events is demonstrated in previous 
studies. The current study aimed at evaluating the effect of vitamin D supplement therapy 
on serum lipids profile, as a risk factor for cardiovascular diseases.
Methods: The current prospective cohort study included 221 patients admitted to a 
university hospital from March 2014 to March 2015. The baseline levels of the patients′ 
serum vitamin D and lipid profile of the study subjects were recorded. After three months 
treatment with vitamin D, the patients′ serum vitamin D level and lipid profile were re-
evaluated. The results before and after the supplement therapy were compared using 
statistical methods.
Results: The mean age of the patients was 48.2 ± 14.0 years. The mean vitamin D level 
was 21.0 ± 16.6 ng/mL at baseline, which increased to 35.8 ± 32.7 ng/mL (P = 0.001) 
after a three-month vitamin D supplement therapy. Mean low-density lipoprotein (LDL) 
decreased from 112.1 ± 30.0 to 98.7 ± 31.7 mg/dL (P = 0.003) after the supplement 
therapy. Mean high-density lipoprotein (HDL) increased from 42.8 ± 11.2 to 44.5 ± 
9.0 mg/dL, but the difference was insignificant before and after the treatment (P = 0.2). 
Mean cholesterol reduced from 183.8 ± 42.3 to 169.5 ± 41.9 mg/dL (P = 0.02) and the 
mean TG dropped from 147.5 ± 98.7 to 134.7 ± 71.1 mg/dL, (P = 0.1) after vitamin D 
intake.
Conclusions: The mean levels of LDL and cholesterol significantly decreased during 
the three-month intervention; in addition, although some changes were observed in the 
level of HDL and TG, the differences were statistically insignificant. Further studies on 
larger sample sizes and longer follow-ups are recommended.
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Vitamin D is one of the main causes of homeostasis in the 
bone and minerals. This vitamin increases the gastrointestinal 
absorption of the calcium and prevents/treats rickets [1]. On 
the other hand, the vitamin D receptors are spread throughout 
the body and therefore, extraskeletal effects of vitamin D are 
predictable [2]. Thus, along with the development of different 
methods to measure 25 (OH) D, which is the most common 
metabolite of vitamin D, several studies were performed to 
evaluate the level of this vitamin and according to their results, 
higher levels of vitamin D is associated with a better health 
status. Therefore, the lower levels of this vitamin can be con-
sidered as a predictor for type 2 diabetes mellitus, cancer, car-
diovascular disorders, immunological problems, and mortali-
ty [3]. In a 11-year study on 4751 patients, subjects with lower 
levels of 25 (OH) D were about 32 times more at risk of mor-
tality, compared with the ones with higher levels of 25 (OH) 
D [4]. In another study on 1739 patients from the offspring of 
the Framingham study, those with serum vitamin D levels of 
lower than 15 ng/mL had a risk ratio of 1.8 to cardiovascular 
events compared with those with 15 ng/mL serum vitamin
D or more [5]. These studies suggested the use of vitamin D 
supplements to improve the general health status [6]. Associ-
ation of vitamin D and cardiovascular disorders may be due 
to the role of this vitamin in decreasing the serum lipid levels 
confirmed by some cross sectional studies [7-9]. The current 
controlled trial aimed at evaluating the effect of vitamin D on 
the serum lipid levels, and examining the impact of vitamin D 
administration on the decrease of serum lipid levels.
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Table 1: Comparison of the Mean Levels of Vitamin D and Lipid Profile, before and after Vitamin D Supplement Therapy
Before therapy after therapy P value
Vitamin level (ng/ml) 21.0 ± 16.6 35.8 ± 32.7 0.001
lDl (mg/dl) 112.1 ± 30.0 98.7 ± 31.7 0.003
HDl (mg/dl) 42.8 ± 11.2 44.5 ± 9.0 0.2
TG (mg/dl) 147.5 ± 98.7 134.7 ± 71.1 0.1
Cholesterol (mg/dl) 183.8 ± 42.3 169.5 ± 41.9 0.02
Data in table are presented as Mean ± SD
LDL, Low density lipoprotein;  HDL, High density lipoprotein; TG,Triglyceride
METHODS
In a prospective, cross sectional study, all the patients above 18 
years old referring to Cardiology Clinic of Loghman-Hakim 
Hospital from March 2014 to March 2015 were prospective-
ly included. The study protocol was approved by the Ethical 
Committee of Shahid Beheshti University of Medical Scienc-
es, Tehran, Iran. On arrival, a blood sample was taken from 
all patients in order to measure the basal level of 25 (OH) 
D, the most valid metabolite of vitamin D. The basal levels 
of the patients’ lipid profile were also recorded. Other vari-
ables including age, gender, and coronary risk factors were 
determined and recorded. The patients then underwent a 
therapeutic regimen including a weekly administration of 
vitamin D 50000 U for three months. In the follow-up visit 
three months after the treatment, a blood sample was retaken 
and 1,25 hydroxyvitamin D and lipid profile were studied in 
all the subjects.
Statistics
The data are expressed as mean ± standard deviation (SD), 
and the categorical variables as percentages. Continuous vari-
ables were compared by the Student t test or the Mann-Whit-
ney U test, based on the distribution of data. Finally, the data 
were analyzed with SPSS version 19. A P-value < 0.05 was 
considered statistically significant.
RESulTS
A total of 221 patients referred to the Cardiology Clinic of 
Loghman-Hakim Hospital were enrolled in the study. The pa-
tients were put on vitamin D supplement. After three months 
of supplement therapy, only 50 patients including 21 (42%) 
males and 29 (58%) females referred for the follow-up visit. 
The mean age of the patients was 48.2 ± 14.0 years. The mean 
vitamin D level was 21.0 ± 16.6 ng/mL on admission. After 
supplement therapy, the mean vitamin D level increased to 
35.8 ± 32.7 ng/mL (P = 0.001). Mean low-density lipopro-
tein (LDL) decreased from 112.1 ± 30.0 to 98.7 ± 31.7 mg/dL 
(P = 0.003). Mean high-density lipoprotein (HDL) increased 
from 42.8 ± 11.2 to 44.5 ± 9.0 mg/dL (P = 0.2). Mean choles-
terol dropped from 183.8 ± 42.3 to 169.5 ± 41.9 mg/dL (P = 
0.02), and the mean triglyceride (TG) reduced form 147.5 ± 
98.7 to 134.7 ± 71.1 mg/dL, (P = 0.1) (Table 1).
DISCuSSION
The results of the current study showed that the mean lev-
els of LDL and cholesterol significantly decreased during the 
three-month of supplement therapy. Although HDL and TG 
were changed, it was not statistically significant. Different 
mechanisms are proposed as the protective factors of vitamin 
D in heart failure. Serum level of 25 (OH) D is a significant 
factor showing the vitamin D reservoir of the body [10]. Re-
ceptor of vitamin D3 (calcitriol) exists in many of the cells 
including cardiomyocytes, endothelial cells, neurons, and 
immunological cells [10, 11]. Calcitriol is one of the most 
important regulators of the calcium metabolism and serum 
calcium homeostasis. Also, it acts as the cytokine excretion 
and intra-cellular calcium metabolism regulator [10-12]. Se-
rum lipid levels have also an important role in the calcium 
metabolism. As previously described, calcium intake affects 
the body mass index (BMI) in different ways, the easiest of 
which, is the inhibition of lipid and free fatty acid absorption 
[13]. It seems that the most important effect of calcium is on 
the extracellular calcium control. Based on the results of dif-
ferent studies, agouti gene is a stimulator of calcium in the 
lipid tissue, which affects the lipolysis and lipogenesis and 
increases the lipid storage in the lipid tissue [14]. Calcitriol 
increases the synthesis of fatty acids and inhibits the calci-
um-dependent lipolysis [15]. Then, entrance of calcium into 
the cells by calcitriol is decreased. Higher intake of calcium, 
decreases the calcium entrance by 1 and 25 dihydroxycho-
lecalciferol, inhibits the synthesis of fatty acids, and triggers 
the lipolytic activity [15]. Decreased plasma insulin by diet 
calcium is another mechanism of this effect. Insulin secretion 
is calcium-dependent and increased calcium is necessary to 
both first and second phases of insulin secretion [16]. Calci-
um also plays an important role in glucose uptake by binding 
to the skeletal cells receptors, insulin receptor affinity, and 
insulin sensitivity [17]. In a review study by Hao Wang et al., 
on 12 clinical trials, the mean change of LDL was 3.23 mg/
dL (0.55 to 5.90 mg/dL), while no changes were detected in 
the level of total cholesterol, TG, and HDL after the adminis-
tration of vitamin D. However, they suggested further studies 
to confirm the effect of vitamin D on serum lipid profile [18]. 
As observed, results of their study were consistent with those 
of the current study in terms of LDL, HDL, and TG, except 
for cholesterol, which significantly decreased in the current 
study.
In a cross sectional study by Manish et al., a total of 107,811 
patients were serially evaluated from 2009 to 2011. Their 
results showed that the patients with vitamin D deficiency 
(serum level less than 20 ng/mL) had lower total cholesterol, 
LDL, and TG, and higher HDL levels compared with those 
with normal levels of vitamin D. Their study also found that 
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increment in the level of vitamin D from 20 to 30 ng/mL 
increased the cholesterol, and HDL significantly compared 
with those of the ones with vitamin D levels lower than 20 
ng/mL [19]. Arslanian et al., showed that vitamin D defi-
ciency was associated with higher lipid and lower HDL in 
both white and African-American children. According to 
their results, 40% of the white children and 73% of the Af-
rican-American children had vitamin D deficiency. A re-
verse relation was found between the concentration of 25 
hydroxyvitamin D and BMI, total body fat, visceral adipose 
tissue (VAT), and subcutaneous adipose tissue (SAT), while 
a direct relation was observed between 25 hydroxyvitamin 
D and HDL. White children with vitamin D deficiency had 
a higher VAT compared with those without vitamin D defi-
ciency, while SAT level was higher in the black children with-
out vitamin D deficiency. Race, season, puberty, and VAT 
were reported as other factors contributing 25 hydroxyvita-
min D deficiency. Vitamin D deficiency is more common in 
blacks and females. They concluded that decreased vitamin 
D level is accompanied by much higher lipid accumulation 
and decreased level of HDL. They therefore suggested that 
the treatment of vitamin D deficiency can affect lipid tissue 
and lipid profile of children and reduce the risk of type 2 dia-
betes mellitus [20].
A study by Schleithoff et al., evaluated the adjusting effects 
of vitamin D on inflammation. They showed that after a 
nine-month treatment with vitamin D in patients with heart 
failure, the inflammatory cytokine of tumor necrosis fac-
tor (TNF)-α decreased and anti-inflammatory cytokine of 
interleukin (IL)-10 increased [21]. In a study by Zittermann 
et al., serum level of vitamin D was significantly lower in 
patients with heart failure compared with the controls [22]. 
Witte et al., showed that low serum level of vitamin D is as-
sociated with the myocyte dysfunction, heart failure, and 
subsequently, acute cardiac death [23]. Many studies showed 
that in patients with metabolic syndrome, vitamin D level is 
lower, while some other studies rejected this hypothesis. In 
a study on 1654 Americans, [24-26] the lower levels of vita-
min D was observed in patients with metabolic syndrome; 
the result was in agreement with those of some other studies. 
In a study by Moy on 380 individuals, subjects with vitamin 
D deficiency were at higher risk for the development of meta-
bolic syndrome (OP = 1.73); in addition, BMI, waist circum-
ference, and TG level were significantly different among the 
ones with normal and vitamin D deficiency [27]. In a study 
in China on 3262 people, the risk of metabolic syndrome was 
almost 1.52 times higher in the ones at the lowest quartile of 
vitamin D compared with the ones on the highest quartile. A 
significant diverse relation was observed between metabolic 
syndrome and level of vitamin D [28]. The most important 
limitations of the current study were the small sample size 
and lack of control group. Also, the study selected patients 
who referred to a cardiology clinic; therefore, the generaliza-
tion of the results should be done cautiously.
CONCluSIONS
Treatment with vitamin D can significantly decrease the level 
of LDL and cholesterol in the patients, although it has no im-
pact on the level of TG and HDL. Other prospective studies 
on the contributing risk factors are suggested in order to eval-
uate the impact of vitamin D level on lipid profile.
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